Founded by University of Pennsylvania complement researcher John D. Lambris, Amyndas Pharmaceuticals develops C3-targeted complement therapeutics for inflammatory and immune-mediated diseases. The company’s patented platform builds on compstatin, the peptide inhibitor discovered in Lambris’ laboratory, with lead programs including AMY-101 and newer candidates designed for longer-lasting treatment of conditions such as age-related macular degeneration.
AUM LifeTech, IncPhiladelphia-based AUM LifeTech develops RNA-targeting therapeutics through its proprietary AUM silence antisense oligonucleotide platform, which is designed to silence or regulate disease-linked RNA without an external delivery vehicle. Founded by biotechnology entrepreneur Veenu Aishwarya, the company is pursuing preclinical treatments for genetically defined diseases, including an anti-FOXP3 cancer-immunotherapy program developed with Children’s Hospital of Philadelphia. Its work also includes a Parkinson’s disease program conducted with the University of Pennsylvania.PHILADELPHIA, PA
Galimedix Therapeutics, IncGalimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing oral and topical small-molecule therapies for neurodegenerative diseases of the eye and brain. Its lead candidate, GAL-101, targets misfolded amyloid beta before toxic oligomers form and is being studied as an eye drop for geographic atrophy, an advanced form of dry age-related macular degeneration. The company’s approach also supports planned development in glaucoma and Alzheimer’s disease, with ophthalmology commercialization backed by Théa Open Innovation.KENSINGTON, MD
Generian PharmaceuticalsFormed by UPMC Enterprises, Generian Pharmaceuticals is a Boston- and Pittsburgh-based preclinical biotechnology company developing orally available small-molecule therapeutics for difficult-to-drug diseases often dominated by biologics. Its discovery platform screens proteins in their native cellular environment, then combines target-binding data with disease-relevant phenotypic testing to advance candidates that modulate protein activity, stability, or degradation. The company’s research includes proprietary programs and a collaboration with Astellas for novel targets.
Franklin BiolabsFranklin Biolabs is a Philadelphia life-sciences company whose team has helped shape genetic medicine for more than four decades, with expertise carried forward from the University of Pennsylvania’s Penn Vector Core. Today, it serves biotechnology, pharmaceutical, and academic researchers as a preclinical CRO, helping advance therapies from early research toward clinical development.325414PHILADELPHIA, PA